28-Jul-2022 | Facts and Factors
According to Facts and Factors, the global gene therapy market size was worth around USD 2,415.10 million in 2021 and is estimated to grow to about USD 7247.58 million by 2028, with a compound annual growth rate (CAGR) of approximately 20.10% over the forecast period. The report analyzes the Gene Therapy market’s drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the Gene Therapy market.
A gene is a basic genetic building block of life that carries a set of instructions for carrying out a certain task. The treatment for cancer, chronic illnesses, infectious diseases, and blood issues is gene therapy. In order to treat or stop the progression of a disease, gene therapy involves replacing defective genes with healthy ones within the body of the patient. One of the main factors propelling the growth of the gene therapy market is the rise in the prevalence of chronic diseases including cancer, uncommon illnesses, genetic disorders, and others. The number of cases of uncommon diseases in the world has increased significantly, fuelling the necessity for cell and gene therapy. Owing to the rise in demand for Gene Therapy, the global Gene Therapy market is estimated to grow at a CAGR of 20.10% during the forecast period.
Browse the full “Gene Therapy Market Size, Share, Growth Analysis Report By Vector Type (Viral Vector and Non-Viral Vector), By Therapy (In Vivo Therapy and Ex Vivo Therapy), By Gene Type (Antigen, Cytokine, Tumour Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others), By Application (Oncological Disorders, Rare Diseases, Neurological Disorders, and Other Diseases), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data and Forecast 2022 – 2028" report at https://www.fnfresearch.com/gene-therapy-market
The increasing occurrence of uncommon illnesses has also increased competition for novel treatments, propelling the gene therapy industry. Ex-vivo gene therapy is gaining popularity for neurological therapies, which will boost gene therapy market growth. The expanding usage of gene manipulation in biotechnology applications, as well as the rising use of genome engineering in a number of treatments, are also projected to guide the gene therapy industry in the next years. High gene therapy prices and a lack of uniformity are predicted to stymie the worldwide gene therapy sector.
Segmental Overview
The Global Gene Therapy Market is segregated based on vector type, therapy, gene type, application, and region. Based on vector type, the market is divided into Viral Vectors and Non-Viral Vectors. Among these, the viral vector segment dominates the market in 2021. Based on therapy, the market is divided into In Vivo Therapy and Ex Vivo Therapy. Over the forecast period, the in vivo therapy segment is expected to develop at the fastest rate in 2021.
Based on gene type, the market is divided into Antigen, Cytokine, Tumour Suppressor, Suicide, Deficiency, Growth factors, Receptors and Others. Among these, the antigen segment dominates the market in 2021. Based on application, the market is divided into Oncological Disorders, Rare Diseases, Neurological Disorders and Other Diseases. Among these, the oncological disorder segment dominates the market in 2021.
Regional Overview
North America is expected to dominate the Global Gene Therapy Market in 2021. Several government authorities are investing in the region due to the presence of a big number of biopharma businesses and a solid regulatory environment for stimulating the growth of cellular treatment. As a result, the regional market is advancing. The existence of gene therapy research and development centers and institutions is projected to propel the market in North America. Over the forecast period, the Asia Pacific regional market is expected to grow at a significant rate in 2021. The rising emphasis on healthcare in India is likely to fuel gene therapy demand throughout the predicted period. A rise in cancer cases in the country is also promoting the use of gene therapy in oncology therapies.
Report Scope
Report Attribute |
Details |
Market Size in 2021 |
USD 2415.10 Million |
Projected Market Size in 2028 |
USD 7247.58 Million |
CAGR Growth Rate |
20.10% CAGR |
Base Year |
2021 |
Forecast Years |
2022-2028 |
Key Market Players |
Novartis AG, Gilead Sciences., Shanghai Sunway Biotech Co. Ltd., Adaptimmune Therapeutics plc., Orchard Therapeutics., Bristol-Myers Squibb., Amgen Inc., Adverum Biotechnologies Inc., Jazz Pharmaceuticals, Shenzhen SiBiono GeneTech, Abeona Therapeutics Inc., Applied Genetic Technologies Corporation, and others |
Key Segment |
By Vector Type, Therapy, Gene Type, Application, and Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
Key Players Insights
Key players functioning in the global Gene Therapy market include Novartis AG, Gilead Sciences., Shanghai Sunway Biotech Co. Ltd., Adaptimmune Therapeutics plc., Orchard Therapeutics., Bristol-Myers Squibb., Amgen Inc., Adverum Biotechnologies Inc., Jazz Pharmaceuticals, Shenzhen SiBiono GeneTech, Abeona Therapeutics Inc., Applied Genetic Technologies Corporation, Intellia Therapeutics, Inc., REGENXBIO Inc., Sangamo Therapeutics, Inc., Astellas Therapeutics Inc., Bluebird Bio, Inc., CRISPR Therapeutics AG, Uniqure N. V., Voyager Therapeutics, Inc., Merck and Co Inc., and Dendron Corporation.
Recent developments:
- In October 2021, the National Institutes of Health, the Food and Drug Administration, ten pharmaceutical companies, and five non-profit groups launched a collaboration to speed up the discovery of gene therapy for the 30 million Americans who suffer from a rare disease. Such activities are anticipated to increase the demand for gene therapy.
- In February 2021, BioMarin Pharmaceutical Inc. provided an update on its investigational gene therapy programs that are currently in clinical development. The Food and Drug Administration (FDA) submitted additional requests to the Company for information needed to remedy the clinical hold issued in September 2021 for the PHEARLESS Phase 1/2 trial of BMN 307.
Global Gene Therapy Market is segmented as follows:
By Vector Type
- Viral Vector
- Non-Viral Vector
By Therapy
- In Vivo Therapy
- Ex Vivo Therapy
By Gene Type
- Antigen
- Cytokine
- Tumor Suppressor
- Suicide
- Deficiency
- Growth factors
- Receptors
- Others
By Application
- Oncological Disorders
- Rare Diseases
- Neurological Disorders
- Other Diseases
By Region
- North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: [email protected]
Web: https://www.fnfresearch.com
